Glucagon Receptor Knockout Prevents Insulin-Deficient Type 1 Diabetes in Mice
Open accessThe DOI matches its Crossref record; 46 of the 47 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To determine the role of glucagon action in the metabolic phenotype of untreated insulin deficiency. RESEARCH DESIGN AND METHODS: We compared pertinent clinical and metabolic parameters in glucagon receptor-null (Gcgr−/−) mice and wild-type (Gcgr+/+) controls after equivalent destruction of β-cells. We used a double dose of streptozotocin to maximize β-cell destruction. RESULTS: Gcgr+/+ mice became hyperglycemic (>500 mg/dL), hyperketonemic, polyuric, and cachectic and had to be killed after 6 weeks. Despite comparable β-cell destruction in Gcgr−/− mice, none of the foregoing clinical or laboratory manifestations of diabetes appeared. There was marked α-cell hyperplasia and hyperglucagonemia (∼1,200 pg/mL), but hepatic phosphorylated cAMP response element binding protein and phosphoenolpyruvate carboxykinase mRNA were profoundly reduced compared with Gcgr+/+ mice with diabetes—evidence that glucagon action had been effectively blocked. Fasting glucose levels and oral and intraperitoneal glucose tolerance tests were normal. Both fasting and nonfasting free fatty acid levels and nonfasting β-hydroxy butyrate levels were lower. CONCLUSIONS: We conclude that blocking glucagon action prevents the deadly metabolic and clinical derangements of type 1 diabetic mice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“While lack of GCGR signaling can normalize glycemia under insulin-deficient conditions15,16, this effect is contingent on the presence of residual insulin17.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
共やくエクイン・エストロゲン(Premarin)服用閉経婦人の血清エクイリン,エストロン,エストラジオール値
Whittaker, P. G., Morgan, M. R., Dean, P., Cameron, E., & Lind, T. (1980) · The Lancet · Cited by 724
The essential role of glucagon in the pathogenesis of diabetes mellitus
Unger, R., & Orci, L. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92375-2 · Cited by 599 · cited 1×
“This idea was proposed previously (9,10) when somatostatin, the first glucagon-suppressing agent to be discovered (6), was found to prevent the acute metabolic consequences of complete insulin lack (7,8).”
BackgroundSelf-citationGelling, R. W., Du, X. Q., Dichmann, D. S., Rømer, J., Huang, H., Cui, L., Obici, S., Tang, B., Holst, J. J., Fledelius, C., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0237106100 · Cited by 563 · cited 5×
“Male mice with global glucagon receptor knockout and wild-type mice (19)”
BackgroundSelf-citationGerich, J. E., Lorenzi, M., Bier, D. M., Schneider, V., Tsalikian, E., Karam, J. H., & Forsham, P. H. (1975) · New England Journal of Medicine · doi:10.1056/nejm197505082921901 · Cited by 354 · cited 1×
“This idea was proposed previously (9,10) when somatostatin, the first glucagon-suppressing agent to be discovered (6), was found to prevent the acute metabolic consequences of complete insulin lack (7,8).”
BackgroundTHE EFFECTS OF TOTAL STARVATION UPON THE LEVELS OF CIRCULATING GLUCAGON AND INSULIN IN MAN*
Unger, R. H., Eisentraut, A. M., & Madison, L. L. (1963) · Journal of Clinical Investigation · doi:10.1172/jci104788 · Cited by 345 · cited 1×
“Glucagon was immunocytochemically localized to pancreatic a-cells (3) and shown to be secreted in response to increased glucose need, as in starvation and exercise (4).”
BackgroundSelf-citationLeptin therapy in insulin-deficient type I diabetes
Wang, M.-Y., Chen, L., Clark, G. O., Lee, Y., Stevens, R. D., Ilkayeva, O. R., Wenner, B. R., Bain, J. R., Charron, M. J., Newgard, C. B., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909422107 · Cited by 327 · cited 6×
“The search for more practical suppressors or antagonists of glucagon has been reenergized by the recent demonstration that leptin can suppress diabetic hyperglucagonemia and reverse the catabolic effects of complete insulin deficiency for extended periods without apparent negative consequences (11,12).”
BackgroundResultSelf-citationCREB controls hepatic lipid metabolism through nuclear hormone receptor PPAR-γ
Herzig, S., Hedrick, S., Morantte, I., Koo, S.-H., Galimi, F., & Montminy, M. (2003) · Nature · doi:10.1038/nature02110 · Cited by 321 · cited 2×
“Uncontrolled insulin deficiency with hyperglucagonemia is characterized by increased gluconeogenesis associated with upregulation of the gluconeogenic enzyme, phosphoenolpyruvate carboxykinase (PEPCK) (29,30).”
BackgroundInsulin within islets is a physiologic glucagon release inhibitor
Maruyama, H., Hisatomi, A., Orci, L., Grodsky, G. M., & Unger, R. H. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111658 · Cited by 303 · cited 1×
“In contrast to normal a-cells, which are restrained by the high local concentrations of intraislet insulin (22), type 1 diabetic a-cells are unregulated, which results in inappropriate hyperglucagonemia (5).”
BackgroundSelf-citationAntidiabetic Effects of IGFBP2, a Leptin-Regulated Gene
Hedbacker, K., Birsoy, K., Wysocki, R. W., Asilmaz, E., Ahima, R. S., Farooqi, I. S., & Friedman, J. M. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2009.11.007 · Cited by 280 · cited 2×
“More recently, the same antidiabetic efficacy has been demonstrated with recombinant leptin (11,23).”
BackgroundUnger, R. H., Eisentraut, A. M., McCall, M. S., & Madison, L. L. (1962) · Journal of Clinical Investigation · doi:10.1172/jci104525 · Cited by 278 · cited 1×
“The development of a radioimmunoassay for glucagon (1) established the hormonal status of this peptide (2), originally considered to be a contaminant of the insulin extraction process.”
BackgroundSelf-citation
Cited by
Items 301–326 of 326
Kotze, P. C. (2015) · SUNScholar (Stellenbosch University) · Cited by 1
Edlund, A. (2016) · Lund University Publications (Lund University)
Ishihara, H. (2013) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.102.3237
Significance of glycaemic control in type 1 diabetes.
Wahid, M., & Naveed, A. K. (2013) · PubMed
Effet hépatique propre du GLP-1 : vers un traitement adjuvant du diabète de type 1 ?
Dubois‐Laforgue, D. (2016) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(16)30105-5
Characterization of Novel Glucagon Receptor Interactors that Modify Receptor Activity
Froese, D. S. (2015) · TSpace (University of Toronto)
The metabolic effects of leptin therapy and glucagon suppression therapy in mouse models of diabetes
Neumann, U. H. (2017) · cIRcle (University of British Columbia) · doi:10.14288/1.0348695
“Glucagon not only plays a role in the fasting state but also in the fed state, which is evident as Gcgr gene deletion can normalize fed blood glucose levels and glucose tolerance [74, 75, 342].”
BackgroundInfluentialProminent Insulin Resistance in Congenital Generalized Lipoatrophy
Wada, J., & Kanwar, Y. S. (2019) · Springer eBooks · doi:10.1007/978-981-13-2977-7_3
Coordinate control of metabolic flux with liver energy status by AMPK in vivo
Hasenour, C. M. (2014)
Vastrad, B. M., & Vastrad, C. M. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.08.447531
Himeno, N., Matsuda, T., & Yoneda, M. (2021) · Diabetology International · doi:10.1007/s13340-021-00527-0
Qi, Y., Guo, X., & Guo, S. (2015) · Springer eBooks · doi:10.1007/978-3-319-12125-3_28-2
Biosynthesis, secretion, and action of glucagon
Lefèbvre, P. J. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch10 · Cited by 1
Bozadjieva, J. A. W. A. E. B.-M. N. (2013) · doi:10.3998/panc.2013.23
Arble, D. M., Hutch, C. R., Hafner, H., Stelmak, D., Leix, K., Sorrell, J. E., Pressler, J. W., Gregg, B. E., & Sandoval, D. A. (2023) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00152.2022 · Cited by 1
Jarry, A., Beyec, J. L., Bado, A., Gautier, J., Riveline, J., Blondeau, B., Guillemain, G., & Gall, M. L. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.23.630024
Kaszoni-Bokor, G. L., Kis, J. T., Szemán, A., Kiss, K. A., Polyák, A., Czégeni, A., Hosszúfalusi, N., Schandl, L., & Winkler, G. (2025) · Orvosi Hetilap · doi:10.1556/650.2025.33407
Loss of Slc39a5 in α-cells impairs glucose metabolism by chronically increasing glucagon
Chen, W. K., Cui, W., Xu, Y. J., Wang, X., Sun, X., Ren, J., Hou, N., Xiong, W., Xiao, R., & Zhang, X. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.11.013
Vastrad, B. M., Pattanashetti, S., Sadashivanavar, V., Pai, K. S. R., & Vastrad, C. M. (2026) · Molecular Diversity · doi:10.1007/s11030-025-11453-7 · Cited by 3
Madhoun, A. S. A., Malik, M. Z., Albeloushi, S., ABUKHALAF, N. A., Miranda, L., Jacob, S., Nizam, R., John, S., GEORGE, P., Channanath, A. M., et al. (2026) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-026-06275-1
“Despite gene duplication, zebrafish GCGR KOs phenocopy key aspects of mammalian GCGR defi - ciency, including hypoglycemia, impaired gluconeogenesis, and altered lipid metabolism [8, 10, 18].”
Role of glucagon in metabolic diseases
Kitamura, T., Tabei, Y., & Kobayashi, M. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70416
“…glucagon in blood glucose regulation became evident through studies showing that blood glucose levels barely increase in pancreatic a -cell-de fi cient or glucagon receptor-de fi cient mice, even after streptozotocin-induced destruction of pancreatic b -cells, which abolishes insulin secretion 1, 3 .”
BindingDB (2016) · UC San Diego · doi:10.7270/q2hm5b7n
Metadata
- Authors
- Lee, Y., Wang, M.-Y., Du, X. Q., Charron, M. J., & Unger, R. H.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Albert Einstein College of Medicine (US)
- VA North Texas Health Care System (US)
- Corresponding author
- Unger, Roger H.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2011-01-21
- Volume
- 60
- Issue
- 2
- Pages
- 391-397
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC3028337
- OpenAlex
- W1986861420
- Cited by
- 327
- References
- 47
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 12 · 2023: 14 · 2022: 19 · 2021: 20 · 2020: 12 · 2019: 16 · 2018: 25 · 2017: 26 · 2016: 32 · 2015: 40 · 2014: 25 · 2013: 23 · 2012: 26
- FWCI
- 32.44
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (R21DK081194, DK081194)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- glucagon receptor, type 1 diabetes, insulin deficiency, beta cell destruction, streptozotocin, alpha cell hyperplasia, hyperglucagonemia, phosphoenolpyruvate carboxykinase, ketogenesis, hyperketonemia, glucose tolerance, free fatty acids, beta-hydroxybutyrate
- MeSH terms
- Animals, Blood Glucose, Diabetes Mellitus, Experimental, Diabetes Mellitus, Type 1, Enzyme-Linked Immunosorbent Assay, Fatty Acids, Glucagon, Hyperglycemia, Immunohistochemistry, Insulin, Insulin-Like Growth Factor I, Liver, Pancreas, Radioimmunoassay, Blotting, Western, Receptors, Glucagon, Mice, Knockout, Reverse Transcriptase Polymerase Chain Reaction, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.